Stifel Nicolaus Sticks to Its Buy Rating for Xenon (XENE)
In a report released on March 10, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Xenon, with a price target of $89.00. The company’s shares closed yesterday at $60.61.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Matteis covers the Healthcare sector, focusing on stocks such as Xenon, Biogen, and VistaGen Therapeutics. According to TipRanks, Matteis has an average return of 15.7% and a 49.29% success rate on recommended stocks.
Xenon has an analyst consensus of Strong Buy, with a price target consensus of $72.94, representing a 20.34% upside. In a report released on March 10, Deutsche Bank also maintained a Buy rating on the stock with a $90.00 price target.
Based on Xenon’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $105.26 million. In comparison, last year the company had a GAAP net loss of $65.69 million
Read More on XENE:
Disclaimer & DisclosureReport an Issue
- Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00
- Xenon Raises $650 Million in Upsized U.S. Equity Offering
- Xenon Pharmaceuticals: Buy Rating Backed by Superior X-TOLE2 Phase 3 Results and Commercial Upside for Azetukalner in Focal Epilepsy
- Xenon Pharmaceuticals price target raised to $64 from $47 at Wedbush
- Xenon Pharmaceuticals price target raised to $90 from $60 at Guggenheim
